Preview

Медицинский вестник Юга России

Расширенный поиск

Отмена препаратов в психиатрии: проблемы и возможности

https://doi.org/10.21886/2219-8075-2020-11-3-6-14

Полный текст:

Аннотация

Многие рекомендации, протоколы описывают показания к началу приема лекарств, но только некоторые из них указывают, когда их приём следует прекратить. Анализ публикаций указывает на дефицит исследований в этой области, особенно в психиатрии. В рамках этого обзора мы постарались предоставить информацию, которая предоставляет ценную информацию об этой процедуре, об опыте других стран. На основании обзора литературы было установлено, что в некоторых странах уже существует консенсус в отношении того, как определить пациента, лечение которого может быть отменено, для этой процедуры были разработаны рекомендации и алгоритмы с минимальным риском для пациента.

Об авторах

Ж. Б. Бибекова
Медицинский Университет Караганды
Казахстан

Жазира Бектурсыновна Бибекова — ассистент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии

Караганда



К. В. Заровный
Медицинский университет Караганды
Казахстан

Кирилл Владимирович Заровный — врач-резидент кафедры неврологии, нейрохирургии, психиатрии и реабилитологии

Караганда



В. О. Цыганова
Казахстанско-Российский медицинский университет
Казахстан

Виктория Олеговна Цыганова — врач-резидент кафедры психиатрии, наркологии и неврологии

Алмата



Список литературы

1. Ailabouni N.J., Nishtala P.S., Mangin D., Tordoff J.M. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. // PLoS One. – 2016. – V.11(4). - e0151066. https://doi.org/10.1371/journal.pone.0151066

2. Reeve E., Shakib S., Hendrix I., Roberts M.S., Wiese M.D. The benefits and harms of deprescribing. // Med J Aust. – 2014. – V.201. – P.386–9. https://doi.org/10.5694/mja13.00200

3. Farrell B., Pottie K., Rojas-Fernandez C.H., Bjerre L.M., Thompson W., Welch V. Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. // PLoS One. – 2016. – V.11(8). - e0161248. https://doi.org/10.1371/journal.pone.0161248

4. Scott I.A., Le Couteur D.G. Physicians need to take the lead in deprescribing. // Intern Med J. - 2015. – V.45(3). – P.352–6. https://doi.org/10.1111/imj.12693

5. Betteridge T.M., Frampton C.M., Jardine D.L. Polypharmacy— we make it worse! A cross-sectional study from an acute admissions unit. // Intern Med J. – 2012. – V.42(2). – P.208– 11. https://doi.org/10.1111/j.1445-5994.2011.02690.x

6. Farrell B., Tsang C., Raman-Wilms L., Irving H., Conklin J., Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. // PLoS One. – 2015. – V.10(4). - e0122246. https://doi.org/10.1371/journal.pone.0122246

7. Reeve E., Wiese M.D. Benefits of deprescribing on patients’ adherence to medications. // International journal of clinical pharmacy. – 2014. – V.36(1). – P.26–9. https://doi.org/10.1007/s11096-013-9871-z

8. Grudnikoff E., Bellonci C. Deprescribing in Child and Adolescent Psychiatry—A Sorely Needed Intervention. // American Journal of Therapeutics. - 2017. – V.24(1). e1-e2. https://doi.org/10.1097/MJT.0000000000000552.

9. Gupta S., Cahill J., Miller R. Deprescribing antipsychotics: A guide for clinicians. // BJPsych Advances. – 2018. – V.24(5). – P. 295-302. https://doi.org/10.1192/bja.2018.2

10. Woodward M.C. Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications. // J. Pharm. Pract. Res. – 2003. – V.33. – P.323–328. https://doi.org/10.1002/jppr2003334323.

11. Sinnott C., Hugh S.M., Boyce M.B., Bradley C.P. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. // Br J Gen Pract. - 2015. – V.65(632). - e184–91. https://doi.org/10.3399/bjgp15X684001

12. Schuling J., Gebben H., Veehof L.J., Haaijer-Ruskamp F.M. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. // BMC Fam Pract. – 2012. – V.13. – P.56. https://doi.org/10.1186/1471-2296-13-56

13. Schoen C., Osborn R., Squires D., Doty M., Pierson R., Applebaum S. New 2011 survey of patients with complex care needs in eleven countries finds that care is often poorly coordinated. // Health Aff (Millwood). – 2011. – V.30(12). – P.2437–48. https://doi.org/10.1377/hlthaff.2011.0923

14. Gupta S., Cahill J. A Prescription for “Deprescribing” in Psychiatry. // Psychiatric services (Washington, D.C.). - 2016. – V.67(8). – P.904-907. https://doi.org/10.1176/appi.ps.201500359.

15. Essock S.M., Covell N.H., Leckman-Westin E., Lieberman J.A., Sederer L.I., et al: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. // Psychiatric Services. – 2009. – V.60(12). – P.1595–1602. https://doi.org/10.1176/ps.2009.60.12.1595

16. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. // Journal of Clinical Psychiatry. – 2004. – V.65(10). – P.1377–1388 https://doi.org/10.4088/jcp.v65n1013

17. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. // Current Medicinal Chemistry. – 2004. – V.11(3). – P.313–327. https://doi.org/10.2174/0929867043456070

18. Gupta S., Miller R. Deprescribing and Its Application to Psychiatry. In: Steingard S. (eds) Critical Psychiatry. Springer, Cham; 2019. https://doi.org/10.1007/978-3-030-02732-2_6

19. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. // Br J Clin Pharmacol. – 2014. – V.78(4). – P.738–47. https://doi.org/10.1111/bcp.12386

20. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. // Schizophr Res. – 1996. – V.20(1-2). – P.145- 151. https://doi.org/10.1016/0920-9964(95)00068-2

21. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. // Psychiatr Serv. – 2006. – V. 57(11). – P. 1636-9. https://doi.org/10.1176/ps.2006.57.11.1636

22. Stanhope V, Ingoglia C, Schmelter B, Marcus SC. Impact of person-centered planning and collaborative documentation on treatment adherence. // Psychiatr Serv. – 2013. – V. 64(1). – P. 76-9. https://doi.org/10.1176/appi.ps.201100489.

23. Jacobson L, Greeley D. What is recovery? A conceptual model and explication. // Psychiatric Services. – 2001. – V. 52(4). – P. 482–5. https://doi.org/10.1176/appi.ps.52.4.482

24. Taylor DJ, Pruiksma KE. Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review. // Int Rev Psychiatry. – 2014. – V.26(2). – P.205-13. https://doi.org/10.3109/09540261.2014.902808

25. Vincent G.K., Velkoff V. The next four decades: The older population in the United States: 2010-2050. // Current Population Reports. – 2010. – P.1-14.

26. Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. // Alzheimers Dement. – 2015. – V. 11(3). – P. 332-84. https://doi.org/10.1016/j.jalz.2015.02.003

27. Renn BN, Asghar-Ali AA, Thielke S, Catic A, Martini SR, et al. A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia. // Am J Geriatr Psychiatry. – 2018. – V.26(2). – P.134-147. https://doi.org/10.1016/j.jagp.2017.09.027

28. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. // Cochrane Database Syst Rev. – 2015. – V.4. - CD001191. https://doi.org/10.1002/14651858.CD001191.pub4.

29. Mitchell SL, Morris JN, Park PS, Fries BE. Terminal care for persons with advanced dementia in the nursing home and home care settings. // J Palliat Med. – 2004. – V.7(6). – P.808- 16. https://doi.org/10.1089/jpm.2004.7.808

30. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? // Drugs Aging. – 2010. – V. 27(6). – P. 435-49. https://doi.org/10.2165/11536760-000000000-00000

31. Vetrano DL, Tosato M, Colloca G, Topinkova E, Fialova D, et al. Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER Study. // Alzheimers Dement. – 2013. – V.9(5). – P.587-93.. https://doi.org/10.1016/j.jalz.2012.09.009.

32. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. // Cochrane Database Syst Rev. – 2006. – V.1. - CD005593. https://doi.org/10.1002/14651858.CD005593

33. Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. // Int J Neuropsychopharmacol. – 2020. – V.23(2). – P. 125–131. https://doi.org/10.1093/ijnp/pyz068

34. Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, et al. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. // Br J Clin Pharmacol. – 2017. – V.83(11). – P.2581-2588. https://doi.org/10.1111/bcp.13369

35. Arah OA, Westert GP, Hurst J, Klazinga NS. A conceptual framework for the OECD Health Care Quality Indicators Project. // Int J Qual Health Care. – 2006. – V.(1). – P. 5-13. https://doi.org/10.1093/intqhc/mzl024

36. Carinci F, Van Gool K, Mainz J, Veillard J, Pichora EC, et al. Towards actionable international comparisons of health system performance: expert revision of the OECD framework and quality indicators. // Int J Qual Health Care. – 2015. – V. 27(2). – P.137-46. https://doi.org/10.1093/intqhc/mzv004

37. Yang SY, Chen LY, Najoan E, Kallivayalil RA, Viboonma K, et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. // Psychiatry Clin Neurosci. – 2018. – V.72(8). – P.572-579. https://doi.org/10.1111/pcn.12676

38. Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, et al. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. // Int J Neuropsychopharmacol. – 2019. – V.22(9). – P.560-573. https://doi.org/10.1093/ijnp/pyz037

39. Binder RL, Levy R. Extrapyramidal reactions in Asians. // Am J Psychiatry. - 1981. – V.138(9). – P.1243–1244. https://doi.org/10.1176/ajp.138.9.1243

40. Ormerod S, McDowell SE, Coleman JJ, Ferner RE. Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis. // Drug Saf. - 2008. V.31(7). – P.597–607. https://doi.org/10.2165/00002018-200831070-00005

41. Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? // Int J Neuropsychopharmacol. – 2020. – V.23(2). – P.125–131. https://doi.org/10.1093/ijnp/pyz068

42. Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. // Can Fam Physician. – 2018. – V.64(1). – P.17-27. PMID: 29358245.

43. Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. // Med J Aust. – 2019. – V.210(4). – P.174-179. https://doi.org/10.5694/mja2.50015

44. Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. // Can Fam Physician. – 2018. – V.64(5). – P.339-351. PMID: 29760253

45. Wallis KA, Andrews A, Henderson M. Swimming Against the Tide: Primary Care Physicians’ Views on Deprescribing in Everyday Practice. // Ann Fam Med. – 2017. – V.15(4). – P.341–346. https://doi.org/10.1370/afm.2094

46. Kouladjian L, Gnjidic D, Reeve E, Chen TF, Hilmer SN. Health Care Practitioners’ Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. // Ann Pharmacother. – 2016. – V.50(8). – P.625‐636. https://doi.org/10.1177/1060028016652997

47. Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and Enablers of Deprescribing: A General Practitioner Perspective. // PLoS One. – 2016. – V.11(4). - e0151066. https://doi.org/10.1371/journal.pone.0151066

48. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. // PLoS One. – 2015. – V.10(4). - e0122246. https://doi.org/10.1371/journal.pone.0122246

49. Sheehan R, Hassiotis A, Walters K, Osborn D, Strydom A, Horsfall L. Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. // BMJ. – 2015. – V.351. - h4326. https://doi.org/10.1136/bmj.h4326

50. Glover G.; Williams R.; et al. Prescribing of Psychotropic Drugs to People with Learning Disabilities and/or Autism by General Practitioners in England. - Public Health England: London, UK, 2015.

51. Flood B. De-Prescribing of Psychotropic Medications in the Adult Population with Intellectual Disabilities: A Commentary. // Pharmacy (Basel). – 2018. – V.6(2). – P.28. https://doi.org/10.3390/pharmacy6020028.

52. British Pharmacological Society. Ten Principles of Good Prescribing. British Pharmacological Society: London, UK, 2012.


Для цитирования:


Бибекова Ж.Б., Заровный К.В., Цыганова В.О. Отмена препаратов в психиатрии: проблемы и возможности. Медицинский вестник Юга России. 2020;11(3):6-14. https://doi.org/10.21886/2219-8075-2020-11-3-6-14

For citation:


Bibekova Z.B., Zarovnyy K.V., Tsyganova V.O. Deprescribing in psychiatry: challenges and opportunities. Medical Herald of the South of Russia. 2020;11(3):6-14. https://doi.org/10.21886/2219-8075-2020-11-3-6-14

Просмотров: 147


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)